Does early intensive multifactorial therapy reduce modelled cardiovascular risk in individuals with screen-detected diabetes? Results from the ADDITION-Europe cluster randomized trial

Diabetic Medicine

Volumn 31, Issue 6, 2014, Pages 647-656

  Black, J A ^a   Sharp, S J ^a   Wareham, N J ^a   Sandbaek A ^b   Rutten, G E H M ^c   Lauritzen, T ^b   Khunti, K ^d   Davies, M J ^d   Borch Johnsen, K ^b,e   Griffin, S J ^a   Simmons, R K ^a  

^a MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e HOLBÆK HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DENMARK; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; UNITED KINGDOM; BIOLOGICAL MODEL; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; EARLY DIAGNOSIS; EPIDEMIOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADULT; AGED; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; EARLY DIAGNOSIS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; TREATMENT OUTCOME;

EID: 84900795459     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12410     Document Type: Article

References (33)

1. Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in Type 2 diabetes. NEngl J Med 2008; 359: 1577-1589.
3. Diabetes UK. Early Identification of People with and at High Risk of Type 2 Diabetes and Interventions for those at High Risk. London: Diabetes UK, 2012.
4. NHS Health Check Programme. Putting Prevention First - NHS Health Check: Vascular Risk Assessment and Management Best Practice Guidance. London: NHS, 2009.
5. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013; 36: S11-S66.
6. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GEHM, Sandbæk A et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011; 378: 156-167.
7. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. World Health Organization. Diabetes Res Clin Pract 1999; 44: 21-26.
8. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G et al. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000; 24: S6-S11.
9. Echouffo-Tcheugui JB, Simmons RK, Williams KM, Barling RS, Prevost AT, Kinmonth AL et al. The ADDITION-Cambridge trial protocol: a cluster-randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. BMC Public Health 2009; 9: 136.
10. Webb DR, Khunti K, Srinivasan B, Gray LJ, Taub N, Campbell S et al. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. Trials 2010; 11: 16.
11. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract 2009; 59: 43-48.
12. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622.
13. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-620.
14. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757-767.
15. Coleman R, Stevens R, Holman R. Updated UKPDS risk engine that estimates primary and secondary cardiovascular disease risk in people with recently diagnosed or established Type 2 diabetes. American Diabetes Association (ADA) Conference. 72nd Scientific Session, 8-12th June 2012, Philadelphia, USA: Diabetes 2012: A103.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
17. White IR, Thompson SG. Adjusting for partially missing baseline measurements in randomized trials. Stat Med 2005; 24: 993-1007.
18. White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. Br Med J 2011; 342: d40.
19. UK Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease (UKPDS 16). Diabetes 1995; 44: 1249-1258.
20. Davies M, Heller S, Skinner T, Campbell M, Carey M, Cradock S et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. Br Med J 2008; 336: 491-495.
21. Andrews RC, Cooper AR, Montgomery AA, Norcross AJ, Peters TJ, Sharp DJ et al. Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial. Lancet 2011; 378: 129-139.
22. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
23. Clifford RM, Davis WA, Batty KT, Davis TM, Fremantle Diabetes Study. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2005; 28: 771-776.
24. Ladhani NN, Majumdar SR, Johnson JA, Tsuyuki RT, Lewanczuk RZ, Spooner R et al. Adding pharmacists to primary care teams reduces predicted long-term risk of cardiovascular events in type 2 diabetic patients without established cardiovascular disease: results from a randomized trial. Diabet Med 2012; 29: 1433-1439.
25. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med 2012; 19: 403-488.
26. Khunti K, Gadsby R, Millett C, Majeed A, Davies M, Drivsholm TB et al. Quality of diabetes care in the UK: comparison of published quality-of-care reports with results of the Quality and Outcomes Framework for Diabetes. Diabet Med 2007; 24: 1436-1441.
27. Drivsholm T, Snorgaard O. Organization of treatment and control of type 2 diabetic patients. Ugeskr Laeger 2012; 174: 2159-2162.
28. Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001; 104: 1577-1579.
29. Chamnan P, Simmons RK, Sharp SJ, Griffin SJ, Wareham NJ. Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia 2009; 52: 2001-2014.
30. Gholap N, Davies M, Patel K, Sattar N, Khunti K. Type 2 diabetes and cardiovascular disease in South Asians. Prim Care Diabetes 2011; 5: 45-56.
31. Webb DR, Khunti K, Gray LJ, Srinivasan BT, Farooqi A, Wareham N et al. Intensive multifactorial intervention improves modelled coronary heart disease risk in screen-detected Type 2 diabetes mellitus: a cluster randomized controlled trial. Diabet Med 2012; 29: 531-540.
32. Canadian Task Force on Preventive Health Care. Recommendations on screening for type 2 diabetes in adults. CMAJ 2012; 184: 1687-1696.
33. Diabetes Australia. Diabetes Management in General Practice: Guidelines for Type 2 Diabetes. Canberra: Diabetes Australia, 2013.